Login
← Go Back
Supriya Lifescience
SUPRIYA · Pharma > Pharmaceuticals & Drugs · Chairman: Satish Waman Wagh · MD: Satish Waman Wagh · Listing date: Dec. 29, 2021
Stock Price vs Company Growth
1d
4.5%
1w
0.2%
1m
11.9%
3m
21.9%
6m
19.8%
1y
18.8%
all
5.3%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 590 4.5%
546
775
Company Overview
Sales
735 Cr
Growth: 12.5%
Profit after Tax
185 Cr
Growth: 1.6%
Small Cap
4,747 Cr
P/E: 25.6x
Industry P/E: 27.1x
Fundamentals
Sales (Cr) ₹ 735
Growth 12.5%
EBITDA 35.9%
P/S 6.5x
Dividend 0.1%
P/E 25.6x
Book Value ₹ 2
PEG Ratio 2.1x
ROE 999.0%
P/B N/A
Shareholding Pattern
Institutions
Promoters
Others
Increase    Decrease    No change
Company Profile Detailed
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.
Belongs to (12 Indices) view more
Investors (5)
jyotsana
rajeev4
shivani....
Followers (1)
varsha96